Department of Paediatric Haematology, Immunology, Rheumatology and Infectious Disease, Emma Children's Hospital, Academic Medical Centre, Amsterdam, The Netherlands.
Clin Exp Rheumatol. 2012 Nov-Dec;30(6):972-8. Epub 2012 Dec 17.
This paper aims to evaluate disease course and outcome of patients in the first 2 years after diagnosis of juvenile idiopathic arthritis (JIA) when treated according to local standard of clinical care, focusing on achievement of inactive disease, functional ability and radiological joint damage.
A retrospective inception cohort study of children with JIA, diagnosed between January 2003 and June 2007 and treated in referral centres in Amsterdam, was carried out. Disease status was determined for every outpatient-clinic visit. Data regarding medication, functional outcome and radiography were recorded.
One hundred and forty-nine consecutive newly diagnosed JIA patients were included. Median age at diagnosis was 11.8 years; median follow-up was 33 months. Synthetic DMARDs (sDMARDs) were used by 95% of patients, including methotrexate in 85%, sulfasalazine in 41% and biologics in 20%. sDMARDs were started within median 1 month after diagnosis. During follow-up, 77% of patients achieved a total of 244 episodes of inactive disease (ID). ID was reached after median 10 months. No baseline predictive factors for achievement of ID could be identified. After 2 years a median CHAQ score of 0.6 was reported. Radiological joint damage occurred at some point in 18 patients (12%); 10 of these patients developed erosions within median 20 months after their first clinic visit.
With current management strategies in daily clinical practice, 77% of newly diagnosed JIA patients achieved a first episode of inactive disease within a median of 10 months. After 2 years, patients reported moderate functional disability and more than 10% showed radiological evidence of joint damage.
本研究旨在评估根据当地临床护理标准接受治疗的幼年特发性关节炎(JIA)患者在诊断后 2 年内的疾病进程和结局,重点关注疾病缓解的实现、功能能力和影像学关节损伤。
对 2003 年 1 月至 2007 年 6 月在阿姆斯特丹转诊中心诊断并接受治疗的 JIA 患儿进行回顾性发病队列研究。每次门诊就诊时都评估疾病状态。记录药物使用、功能结局和影像学数据。
共纳入 149 例新诊断的 JIA 患者。诊断时的中位年龄为 11.8 岁,中位随访时间为 33 个月。95%的患者使用了合成改善病情抗风湿药(sDMARDs),包括 85%的甲氨蝶呤、41%的柳氮磺胺吡啶和 20%的生物制剂。sDMARDs 在诊断后中位 1 个月内开始使用。在随访期间,77%的患者总共出现了 244 次缓解期(ID)。ID 在中位 10 个月后达到。无法确定 ID 实现的基线预测因素。2 年后,中位 CHAQ 评分为 0.6。18 名患者(12%)在某个时间点出现了影像学关节损伤;这些患者中有 10 名在首次就诊后中位 20 个月内出现了侵蚀。
在当前的日常临床实践管理策略下,77%的新诊断 JIA 患者在中位 10 个月内出现首次 ID。2 年后,患者报告有中度的功能障碍,超过 10%的患者出现影像学关节损伤证据。